Abstract | The IL-6 family of cytokines consists of IL-6, IL-11, IL-27 , IL-31, oncostatin M (OSM), leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1) and cardiotrophin-like cytokine factor 1 (CLCF1). Membership of this cytokine family is defined by usage of common β-receptor signalling subunits, which activate various intracellular signalling pathways. Each IL-6 family member elicits responses essential to the physiological control of immune homeostasis, haematopoiesis, inflammation, development and metabolism. Accordingly , distortion of these cytokine activities often promotes chronic disease and cancer ; the pathological importance of this is exemplified by the successful treatment of certain autoimmune conditions with drugs that target the IL-6 pathway. Here, we discuss the emerging roles for IL-6 family members in infection, chronic inflammation, autoimmunity and cancer and review therapeutic strategies designed to manipulate these cytokines in disease.
Cytokines contribute to all aspects of human biology and have evolved to enable the sensing and interpretation of environmental cues relevant to the maintenance of normal host physiology 1 . Although these secretory proteins are best known for their role as custodians of immune homeostasis and the inflammatory response to infection, trauma or injury, their diverse functions also affect embryonic development, cognitive function and behaviour, tissue integrity and ageing. In this regard, cytokines often display pleiotropic or overlapping functional properties 1 . The IL-6 cytokine family comprises IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM), leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1) and cardiotrophin-like cytokine factor 1 (CLCF1), and among all cytokine families, it arguably displays the highest degree of functional pleiotropy and redundancy in eliciting responses relevant to health and disease 2 . Members of this family play prominent roles in chronic inflammation, autoimmunity, infectious disease and cancer (Box 1), where they often act as diagnostic or prognostic indicators of disease activity and response to therapy 1, [3] [4] [5] [6] . Moreover, IL-6 family cytokines are now viewed as major therapeutic targets for clinical intervention [3] [4] [5] [6] [7] [8] [9] . This is epitomized by the treatment of chronic immune-related conditions, such as inflammatory arthritis, giant cell arteritis and Castleman disease, with drugs that target IL-6 (refs 5,10-12 ).
In this Review, we draw on recent advances to provide a timely update on the biology of IL-6 family cytokines and their clinical potential as therapeutic targets or disease modifiers in autoimmunity, inflammation, infection and cancer.
What constitutes IL-6 family membership? IL-6 remains the archetypal member of the IL-6 cytokine family and regulates a diverse array of functions relevant to haematopoiesis, tissue homeostasis, metabolism and immunity 5, 13 (Boxes 1,2). Since the discovery of IL-6, subsequent investigations have revealed a high degree of functional redundancy among IL-6 family cytokines 14 . As a consequence, cytokines within this family are often described with activities attributed to lymphokines, adipokines or myokines, which reflect their broad expression and cellular distribution among all major cell types within the body. This redundancy is characterized by a precise hierarchical involvement in inflammation, metabolism, development, tissue regeneration, neurogenesis and oncogenesis 15 
(Boxes 1,2).
A defining feature of this cytokine family is its usage of common cytokine receptor subunits. These receptor complexes comprise the shared signal-transducing receptor β-subunit, membrane glycoprotein 130 (gp130; also known as IL-6Rβ), together with either a ligandbinding non-signalling receptor α-subunit or a signalling receptor β-subunit that resembles gp130 (refs 2,15,16 ) ( fig. 1 ). The receptor signalling complexes for IL-6 and IL-11 contain a gp130 homodimer, whereas other family members signal via a heterodimeric receptor complex containing gp130 and an alternative signalling β-subunit ( fig. 1 ). The exception to this 'gp130 rule' is IL-31, which binds a cytokine receptor complex containing the OSM-specific receptor subunit-β (OSMRβ) and a cognate IL-31-binding receptor termed IL-31 receptor subunit-α (IL-31Rα) [17] [18] [19] . Phylogenetic analysis of cytokine families reveals that members of the IL-6 family share a close relationship with IL-12 family cytokines [20] [21] [22] . This link is illustrated by the heterodimeric composition of IL-27 (comprising IL-27p28 (also known as IL-27α) and Epstein-Barr virusinduced gene 3 protein (EBI3; also known as IL-27β)), which is structurally related to the IL-12 (IL-12p40 (also known as IL-12β)-IL-12p35 (also known as IL-12α)), IL-23 (IL-23p19 (also known as IL-23α)-IL-12p40), IL-35 (IL-12p40-EBI3) and IL-39 (IL-23p19-EBI3) hetero dimers [23] [24] [25] . Interestingly, both IL-27p28 and IL-35 can also signal via gp130 (refs 26,27 ), although the biological importance of this engagement with gp130 requires further substantiation, and thus their membership to the IL-6 family of cytokines is premature.
The functional diversity and redundancy associated with IL-6 family cytokines is partially explained by the presence of the ubiquitously expressed common gp130 signal-transducing receptor ( fig. 1) . Use of the common gp130 receptor subunit contributes to the regulation of a wide range of overlapping activities that are controlled by IL-6 family cytokines. As a consequence, these cytokines play key roles in many physiological processes, including development, as evidenced by the embryonic lethality of gp130-deficient mice 28 . In contrast to gp130, the receptor subunits specific to individual family members display a more restricted cellular expression profile, and the phenotype of mice lacking individual cytokine family members or their associated receptor subunits is often less severe than their apparent pleiotropic properties would suggest [28] [29] [30] [31] . While the tissue distribution of these receptors offers some distinction as to how individual family members act in defined cellular compartments, certain cytokines within the family have evolved several mechanisms that amplify or broaden their cellular activities. For example, human OSM can signal via gp130-LIF receptor (LIFR) or gp130-OSMRβ complexes to mediate responses typically associated with LIF (for example, haematopoiesis) 17 .
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Adipokines A subset of cytokines that are secreted by adipose tissue and are sometimes called adipocytokines.
Myokines
Cytokines produced and released by myocytes in response to muscle contraction.
Box 1 | Signalling mechanisms for IL-6 family cytokines and links with physiological and disease processes
Intracellular signalling mechanisms linked to the membrane glycoprotein 130 (gp130) receptor system are triggered via activation of receptorassociated cytoplasmic tyrosine kinases (Janus kinase 1 (JAK1), JAK2 and non-receptor tyrosine-protein kinase 2 (TYK2)). Activation of these proteins leads to distinct patterns of tyrosine phosphorylation and subsequent activation of the latent transcription factors signal transducer and activator of transcription 1 (STAT1), STAT3 and, to a lesser extent, STAT5. Additional signalling mechanisms associated with cytokine activation of the gp130 receptor system include processes controlled through the tyrosine-protein phosphatase SH-PTP2 (SHP2). The activation of this protein promotes signalling through the RAS-RAF pathway and the SRC-YAP-NoTCH pathway. Activation of the RAS-RAF cascade also regulates several downstream modifiers that include the phosphory lation of mitogen-activated protein kinases (mAPKs) and the RAC serine/threonine-protein kinase (AKT) and mechanistic target of rapamycin complex 1 (mToRC1) pathways and activities associated with the transcription factors nuclear factor NF-Il-6 (a CAAT/enhancer binding protein (C/eBP) family member) and activator protein 1 (AP-1) (a heterodimer of proto-oncogene JuN and proto-oncogene FoS). other kinases with less defined involvements with this receptor system include serine/threonine-protein kinase SAK (also known as PlK4), tyrosine-protein kinase HCK, tyrosine-protein kinase FeS/FPS (FeS), tyrosine-protein kinase BTK and tyrosine-protein kinase TeC 16 . each of these signal transduction mechanisms controls various biological processes, as indicated. The heat map depicted in the right-hand panel details how individual Il-6 cytokine family members contribute to specific physiological and immunological processes and emphasizes their relative importance in certain disease settings (depicted below the blue line).
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Receptor promiscuity can also elicit defined forms of cytokine receptor crosstalk. For instance, CNTF displays a low affinity interaction with IL-6 receptor subunit-α (IL-6Rα) that can lead to the formation and activation of an IL-6Rα-gp130-LIFR signalling receptor complex 2, 32 . Such cross-regulation may afford CNTF the capacity to control IL-6-related processes not normally associated with its primary involvement in the nervous system (for example, metabolism, bone remodelling and immune regulation) 33, 34 (Boxes 1,2). The complexities of IL-6Rα usage also extend to cytokines beyond the IL-6 cytokine family, with a recent example being IL-27p28, which moderates inflammatory activities through engagement of an IL-6Rα-gp130 receptor system 27, 35, 36 .
In addition to these classical mechanisms of cytokine receptor signalling, several members of the IL-6 family employ alternative modes of gp130 activation termed cytokine trans-signalling (relevant to IL-6, IL-11 and CNTF) and trans-presentation (relevant to IL-6) (Box 3). These alternative modes of cytokine signalling are best epitomized by the action of IL-6, and we refer the reader to several recent articles that review the regulation and biological properties of classical IL-6 receptor (IL-6R) signalling and IL-6 trans-signalling in health and disease 5, 15, 17, [37] [38] [39] [40] . Briefly, classical IL-6R signalling describes activities mediated via the membrane-bound IL-6R complex and is restricted to cells that express both IL-6Rα and gp130 (ref.
37
). By contrast, IL-6 transsignalling denotes a process that involves IL-6 binding to a soluble form of IL-6Rα (sIL-6R), which maintains the circulating half-life of IL-6 and increases its bioavailability 41, 42 . Interestingly, sIL-6R shares sequence identity with both IL-12p40 and EBI3, and once bound with IL-6 resembles a heterodimeric cytokine similar to IL-12-related cytokines 5, 20, 43 . In this regard, the IL-6-sIL-6R complex is able to directly engage and activate membrane-bound gp130 to facilitate IL-6 signalling in cell types that would not normally respond to IL-6 (ref.
). Thus, trans-signalling serves to broaden the target cell repertoire of IL-6 and is considered the primary mechanism for IL-6 involvement in numerous chronic diseases and cancers 5, 37, 39 . Intriguingly, similar cytokine trans-signalling mechanisms have been described for IL-11 and CNTF, and recent in vitro observations imply that both IL-27p28 and EBI3 can also induce sIL-6R-mediated forms of trans-signalling 2, 15, 36, [44] [45] [46] (Box 3).
While the in vivo consequences of these latter signalling modes require further evaluation, the identification of soluble variants of gp130 (sgp130) in human serum, urine and inflammatory exudates that antagonize both IL-6 and IL-11 trans-signalling emphasizes the biological importance of these alternative signalling mechanisms 17, 37, 40, 46 .
Regulation of intracellular signalling
All IL-6-related cytokine receptor complexes transduce intracellular signals via t he Janus kinase-signal transducer and activator of transcription pathway (JAK-STAT pathway), where receptor-associated JAKs (namely, JAK1, JAK2 and TYK2) activate the latent transcription factors STAT1, STAT3 and (to a lesser extent) STAT5 (refs 6,9,16 ) (Box 1).
Other signalling intermediates activated in response to IL-6 family cytokines include, first, the protein tyrosine phosphatase SH-PTP2 (SHP2; also known as PTPN11), which promotes activation of the RAS-RAFextracellular-signal-regulated kinase 1 (ERK1)/ERK2 mitogen-activated protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K)-protein kinase B (PKB; also known as AKT) pathways, and, second, the transcription factor nuclear factor NF-IL-6 (also known as C/EBPβ) 16 (Box 1). Recently, IL-6-induced and IL-11-induced activation of PI3K was shown to regulate the mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) system, which controls telomerase activity and protein synthesis and influences various cellular processes including metabolism and redox stress 47, 48 NATuRe RevIewS | ImmunoLogy Box 2 | IL-6 family cytokines as regulators of metabolic processes members of the Il-6 cytokine family perform integral roles in health and disease, and their capacity to influence the maintenance of immune homeostasis and wellbeing can occur via regulation of various metabolic processes. The depicted heat map summarizes the relative contribution of individual members of the Il-6 cytokine family to metabolism and emphasizes the types of metabolic processes that they affect. Certain family members, such as Il-6 and oncostatin m (oSm), elicit these effects in various stromal tissue compartments (for example, muscle, liver, bone and brain) and inflammatory cells (for example, lymphocytes and macrophages) [242] [243] [244] . on the other hand, Il-27 displays a more restricted activity profile on select immune cell types, where it controls the expression of enzymes responsible for oxysterol generation in effector and regulatory CD4 + T cells
245
. Importantly, several of these associations with metabolism have been identified through clinical observations in patients receiving biological drugs. For example, hypoferraemia is a common response to systemic infection, and patients with autoimmune conditions, such as rheumatoid arthritis, frequently suffer from inflammatory anaemia 246 . Here, biological drugs against Il-6 (for example, tocilizumab) combat the development of anaemia and inhibit the hepatic-derived generation of hepcidin and haptoglobin 247, 248 . These latter responses are also associated with oSm and leukaemia inhibitory factor (lIF) 249 . Further roles for Il-6 in metabolic processes have been identified in Il6 −/− mice, which develop mature-onset obesity, hypertriglyceridaemia and glucose intolerance, and patients on tocilizumab experience changes in serum cholesterol and triglyceride levels, along with increases in body weight 10, 250, 251 . The control of adipogenesis and lipolysis is also attributed to other Il-6 family cytokines, and these are reviewed elsewhere [252] [253] [254] . For instance, ciliary neurotrophic factor (CNTF) treatment in mice reduced adiposity and body weight and improved various parameters of diabetes and hepatic steatosis, a finding that led to the development of recombinant CNTF therapy (axokine), which suppressed appetite, increased energy expenditure and caused sustained weight loss in humans [255] [256] [257] . Consistent with a role for Il-6 family cytokines in regulating energy and glucose metabolism, acute infusion of Il-6 in mice increased glucose uptake and fatty acid oxidation in skeletal muscle, which was associated with improved insulin sensitivity and protection from diet-induced obesity 258 .
Here, Il-6 released from contracting muscle drives the production of glucagon-like peptide 1 (GlP-1) within the gut and pancreas and contributes to the maintenance of glucose homeostasis through GlP-1 control of insulin secretion 259 . An important aspect of these metabolic-associated outcomes regulated by Il-6 family members is their link with alterations in mitochondrial activity. These include changes in mitochondrial remodelling because of cachexia, alterations in mitochondrial calcium mobilization and membrane potential and the regulation of thermogenesis through regulation of mitochondrial brown fat uncoupling protein 1 (refs 260-266 ). 
CLCF1, cardiotrophin-like cytokine factor 1.
Janus kinase-signal transducer and activator of transcription pathway (JAK-sTAT pathway). A cytokine receptor signalling mechanism used by certain cytokines to sense and interpret environmental cues during inflammation and immune homeostasis.
(Box 1). The diverse signalling networks activated by IL-6 also extend to NOTCH and Yes-associated protein (YAP), which upon gp130-SRC kinase-dependent activation facilitate epithelial cell proliferation and tissue remodelling or regeneration 49 (Box 1).
The pathophysiological consequences of dysregulated gp130 activation on immune homeostasis and susceptibility to infection, autoimmunity or cancer have been widely reported, thus highlighting the importance of restricting the magnitude or duration of IL-6 cytokine family signalling in disease [50] [51] [52] [53] [54] . In this respect, multiple negative regulatory mechanisms have evolved to curtail gp130-dependent signalling. These include receptor internalization, deactivation of receptors and signalling intermediates by protein tyrosine phosphatases, microRNA (miRNA)-mediated translational repression and degradation of target mRNAs encoding cytokines or their receptors and the STAT-driven induction of protein inhibitor of activated STAT protein (PIAS) and suppressor of cytokine signalling (SOCS) factors 9, 16, 55, 56 . Among these, SOCS3 plays the predominant negative regulatory role by inhibiting JAK-STAT3 activation and targeting cytokine receptor complexes for proteasome degradation 55 . Considering the global cellular processes activated by the above signalling cascades, it is not surprising that IL-6 family cytokines display widespread functional pleiotropy (Box 1). So, how do individual family members acquire unique biological specificity? Early investigations of STAT factors and their interaction with the genome provided evidence of cooperative mechanisms with other transcription factors, competition for overlapping transcription factor binding sites in gene promoter regions and interaction with other transcriptional co-activators or co-repressors 9, 55, 57 . For example, the STAT3-mediated transcriptional output of IL-6 family cytokines can be influenced by the interaction of STAT3 with co-activators (such as p300-CREB-binding protein (CBP)) and other transcription factors, including nuclear factor-κB (NF-κB). NF-κB complexes with STAT3 in an unphosphorylated state to drive a distinct transcriptional signature enriched for genes involved in oncogenic and immune responses 58 . Interestingly, there is also an alternative mode of transcriptional control employed by STAT3. This occurs downstream of IL-6 and IL-11 and involves the induction of specific miRNAs implicated in tumorigenesis and epithelialmesenchymal transition (EMT) (for example, miR-21 and miR-200 family members) 59, 60 . Another mechanism by which individual IL-6 family members achieve biological specificity involves Members of the IL-6 cytokine family share a common ancestral link to an innate immune sensing mechanism found in Drosophila melanogaster (part a). This system consists of Unpaired 3 (IL-6-like), Domeless (gp130-like), Hopscotch (Drosophila melanogaster homologue of mammalian Janus kinase (JAK)) and signal transducer and activator of transcription protein at 92E (Stat92E; also referred to as Marelle). In mammals, all cytokines within the family activate cells through receptor complexes that contain the signal-transducing receptor β-subunit membrane glycoprotein 130 (gp130) (parts b and c). Three distinct forms of cytokine receptor arrangements are utilized by these cytokines. Receptor complexes for IL-6 and IL-11 (part b) contain a cognate non-signalling receptor α-subunit and gp130 (termed a gp130 homodimer receptor complex), with gp130 existing as a homodimer to elicit signalling. On the basis of the proposed structural arrangement of the IL-6 receptor (IL-6R), a functioning receptor is composed of an IL-6-IL-6R-gp130 complex that is clustered into a dimer structure 16, 268 . By contrast, receptor complexes for leukaemia inhibitory factor (LIF), cardiotrophin 1 (CT-1), oncostatin M (OSM) and IL-27 (part c) comprise gp130 and a second receptor subunit, which contains structural features similar to gp130 (termed a gp130 heterodimer receptor complex). These include LIF receptor (LIFR), OSM-specific receptor subunit-β (OSMRβ) and IL-27 receptor subunit-α (IL-27Rα). The receptor for ciliary neurotrophic factor (CNTF) and cardiotrophin-like cytokine factor 1 (CLCF1) comprises three individual receptor subunits formed between CNTF receptor subunit-α (CNTFRα), LIFR and gp130. Currently , IL-31 remains the only exception to this 'gp130 rule', and the IL-31 receptor consists of IL-31 receptor subunit-α (IL-31Rα) and OSMRβ. These alternative receptors provide cytokine specificity and couple directly to signal transduction pathways required for cellular activation (Box 1). GPI, glycosylphosphatidylinositol; IL-11R , IL-11 receptor.
cross-regulation between individual STAT proteins 9, [61] [62] [63] [64] . For example, in cells lacking STAT1, STAT1-activating cytokines (for instance IFNγ) show enhanced STAT3-type responses, such as increased cell survival, proliferation and induction of immune tolerance. Conversely, in STAT3-deficient cells, IL-6 induces STAT1-associated cellular effects, such as inhibition of cell proliferation, induction of apoptosis and promotion of antitumour immunity 9, 62, 64 . Notably, a series of studies investigating the differential transcriptional responsiveness of T cells to IL-6 and IL-27 has uncovered novel insights into how cross-regulation between STAT1, STAT3 and STAT5 can determine the effector characteristics of CD4 + T helper cells 9, 65, 66 . Specifically, while both cytokines transcriptionally regulate a comparable number of genes, a small number of immunoregulatory genes was differentially expressed (for example, Ifng, Ccl5 and Rorc), which reflect the opposing pro-inflammatory and immunosuppressive functions assigned to IL-6 and IL-27 (ref.
66
).
In this setting, STAT3 provided the bulk of the overall transcriptional responsiveness to each cytokine, while STAT1 shaped the transcriptional programme specific to either IL-6 or IL-27.
Critical modulators of innate immunity
During inflammation, IL-6 family cytokines regulate innate immunity through direct effects on innate immune cells and indirectly via activation of stromal tissue cells resident to the site of inflammation (Box 1). These activities influence changes in leukocyte recruitment, their functional activation, differentiation and survival and the development of a more sustained adaptive immune response 5, 15, 17, 67 . Importantly, such roles illustrate why therapeutic targeting of IL-6 family members has been often associated with clinical benefit in inflammatory diseases, where these processes are distorted or skewed.
The capacity of IL-6 family cytokines to regulate almost every aspect of the innate immune system is facilitated, at least in part, by their signalling interplay with the complement system and pattern recognition receptors 68, 69 . For example, IL-6R, complement component C5a receptor 1 (C5AR1) and Toll-like receptor 4 (TLR4) signalling pathways share a complex interaction that is relevant to the control of bacteraemia and sepsis [70] [71] [72] . Such interactions may include the collaborative crosstalk that exists between STAT3 and NF-κB 73, 74 . Thus, IL-6 and other IL-6-related cytokines often work in association with innate sensing systems to link innate and adaptive immunity and to control antimicrobial defence.
Studies on IL-6, IL-27, OSM and LIF highlight important roles for these cytokines in antimicrobial and antiviral immunity, where they provide tissue protection from infection-related injury 30, 67, 70, [75] [76] [77] . These cytokines often control the recruitment, adhesion, survival and effector activities of neutrophils, tissue-resident and inflammatory monocytes, and innate lymphoid cell populations (for example, natural killer (NK) cells). Specifically, these activities include the regulation of neutrophil-activating chemokines (for example, CXC-chemokine ligand 1 (CXCL1), CXCL5, CXCL6 and CXCL8), adhesion molecules (for example, intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion protein 1 (VCAM1) and L-selectin) and apoptotic regulators (for example, apoptosis regulator BCL-2 and apoptosis regulator BCL-X L (also known as BCL2L1)) 39, 78 . In this regard, several in vivo studies have shown that IL-6 family cytokines affect the accumulation of specific immune cell subsets within inflamed tissues [79] [80] [81] [82] . For instance, IL-6 deficiency leads
Pattern recognition receptors
innate sensors that detect bacteria, viruses, fungi and other endogenous ligands generally associated with tissue damage.
Box 3 | Receptor signalling mechanisms used by the IL-6 family of cytokines
Several members of the Il-6 family adopt alternative modes of cellular activation via membrane glycoprotein 130 (gp130). For example, Il-6 classical cytokine receptor signalling transduced via a gp130 homodimer is facilitated by membrane-bound forms of Il-6 receptor subunit-α (Il-6Rα) and gp130 (for schematic purposes, only one gp130 molecule is shown). Soluble forms of the cognate non-signalling receptor α-subunits for Il-6 (sIl-6Rα), Il-11 (sIl-11R) and ciliary neurotrophic factor (CNTF) (sCNTFR) are readily detected in serum. These soluble receptors retain cytokine-binding kinetics and form receptor-ligand complexes that activate cells through binding interactions with cell-associated gp130. Cytokine binding to soluble receptors also increases the circulating half-life of the cytokine and offers protection from proteolytic degradation 40 . These forms of cellular activation are termed cytokine trans-signalling and provide a mechanism to broaden the types of cells that are responsive to Il-6, Il-11 or CNTF 2 . Recent evidence has identified another form of receptor engagement termed Il-6 transpresentation 267 . Here, Il-6 bound to membrane-bound Il-6Rα is displayed on the surface of cells (for example, specialized dendritic cells) and presented to gp130 expressed on a nearby cell type (for example, a lymphocyte) to elicit signalling via a gp130 homodimer (for schematic purposes, only one gp130 molecule is shown). These additional forms of cytokine receptor signalling contribute to the regulation of innate and adaptive immunity and direct responses in target cells that lack specific receptors for these cytokines. Also shown are the numerous cellular processes associated with each of these signalling modes. 
Neutrophil function is, however, impaired in Il6
−/− mice infected with Candida albicans, which may account for the loss of infection control and increased dissemination of the pathogen in these mice 84 . Interestingly, these activities are not directly governed by IL-6 acting on the neutrophil infiltrate. Instead, neutrophil phagocytosis and killing are controlled by inflammatory mediators released by stromal tissue cells, such as endothelial, smooth muscle, epithelial and mesothelial cells and fibroblasts, in response to IL-6 trans-signalling 39 . In this scenario, the local regulation of IL-6 trans-signalling is reliant on the initial neutrophil infiltrate, which secretes sIL-6R within the inflamed tissue as a response to specific stimuli (for example, C-reactive protein, inflammatory chemokines, complement components, bioactive lipids and N-formyl peptides) 5, 39 . Thus, sIL-6R is an alarmin that affects innate and adaptive immune outcomes 37, 39 . The importance of this form of IL-6 regulation is exemplified by individuals carrying a specific IL6R polymorphic mutation (rs2228145) 5, 37, 85, 86 . These individuals display heightened levels of circulating sIL-6R, and this is associated with reduced markers of systemic inflammation and lower risk of coronary heart disease 87, 88 . While these findings appear counterintuitive given the proposed importance of IL-6 trans-signalling in chronic and autoimmune diseases, one must consider the wider properties of a soluble cytokine receptor 17, 37, 40 . These include maintaining the circulating half-life of the cytokine. In this context, the heightened sIL-6R levels complex with IL-6 and increase the bioavailability of the IL-6-sIL-6R complex for antagonism by sgp130 to impair IL-6 signalling capacity 17, 37, 40 . What about the other IL-6-related cytokines? While the phenotypic characteristics of mice lacking IL-6, IL-11, LIF or CNTF reveal a degree of functional redundancy [28] [29] [30] [31] , individual cytokines sit within a defined hierarchy. For example, in models of autoimmunity (such as inflammatory arthritis), Il6 −/− and Il6ra −/− mice are protected, whereas Il11ra −/− and Osmrb −/− mice develop a disease severity comparable to wild-type mice 89 . Instead, Il11ra −/− and Osmrb −/− mice display other aspects of pathology, including impaired hepatocyte proliferation, altered bone turnover and monocytic cell trafficking, thymic hyperplasia and glomerulonephritis [90] [91] [92] [93] . These studies illustrate the involvement of IL-6-related cytokines in immune homeostasis and innate immune activation and emphasize the context-dependent nature of their activities. Understanding these subtle differences and their biology is essential when considering the design or clinical application of therapeutic interventions that target members of the IL-6-related family.
Orchestrators of adaptive immunity
The regulatory capacity of IL-6-related cytokines in adaptive immunity is defined by their effects on the mat uration of B cells into antibody-secreting cells, the survival and maintenance of long-lived plasma cells and the generation of lymphocytes with defined phenotypic or effector characteristics. While these activities often rely on the prior activation of innate immune responses in monocytes and specialized antigen-presenting cells, several IL-6 family cytokines (for example, IL-6 and IL-27) also act as lymphokines of adaptive immunity (Box 1). For instance, IL-6 controls the effector characteristics of various CD4 + T helper cell populations, with initial investigations showing that IL-27 instructs T helper 1 (T H 1) cell development and promotes expression of IFNγ, the T H 1 cell transcriptional regulator T-BET, STAT1 and IL-12 receptor subunit β2 (IL-12Rβ2) 5, 23, 67, 94 . The role of IL-27 has since been broadened to include negative regulation of IL-2 signalling and restriction of the development of immune responses through the expansion of T-BET + CXC-chemokine receptor 3 (CXCR3) + regulatory T (T reg ) cell populations in T H 1 cell-mediated models of inflammation (such as acute Listeria monocytogenes infection) [95] [96] [97] [98] [99] [100] [101] . Thus, IL-27 is often protective in mouse models of chronic infection (for example, leishmaniasis and toxoplasmosis) and autoimmunity (for example, inflammatory arthritis and chronic inflammation of the central nervous system), and Il27ra −/− mice typically develop heightened or adverse T cell-mediated disease 23, 67 . By contrast, IL-6 drives tissue-specific pathology and fibrosis through the expansion of IFNγ-secreting T H 1 cells A similar interaction may also apply to IL-11 and OSM, which have been reported to drive or inhibit T H 17 cell development, respectively 107, 108 . However, it is unclear whether these alternative roles of IL-11 and OSM control the expansion of T H 17 cell populations in draining lymph nodes or affect the maintenance of pathogenic effector T cells in inflamed tissues.
As discussed earlier, the contrasting lymphokine properties of IL-6 and IL-27 are primarily controlled by subtleties in the regulation of STAT1 and STAT3 (ref.
109
). Among IL-6 family cytokines, only IL-27 preferentially activates STAT1, and this IL-27-STAT1 axis often inhibits the IL-6-mediated control of STAT3 to alter the effector or regulatory characteristics of T cell subsets 94 . This is exemplified by the ability of IL-27 to block the commitment towards T H 17 cells through STAT1 control of STAT3 signalling 66, [110] [111] [112] [113] . This inhibitory signal is lost in STAT1-deficient T cells, where IL-27 switches to promote expansion of T H 17 cell populations via STAT3 (refs 66,110 ). Thus, alterations in the balance of cytokine-driven STAT1 and STAT3 signalling may yield distinct biological outcomes, which will shape the pattern of adaptive immunity controlled by IL-6-related cytokines. For example, while IL-6 inhibits T reg cell function and prevents the conversion of T H 17 cells into T reg cells, IL-27 stimulates suppressive T reg cell activities that regulate the expression of cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed cell death 1 (PD1) [114] [115] [116] [117] [118] . The challenge now is to understand how IL-6-related cytokines influence the pathogenesis and clinical management of disease through activation of these immunological outcomes.
Determinants of chronic autoimmune diseases
With impact on stromal tissue cells, tissue-resident monocytes and activated inflammatory leukocytes, IL-6 family cytokines play vital roles in the initiation, maintenance and resolution of local and systemic inflammatory outcomes that promote tissue damage, activation of the acute-phase response, development of autoimmune reactions and metabolism 5, 15, 17, [119] [120] [121] [122] [123] (Boxes 1,2). As a consequence, IL-6 family cytokines play a central role in the progression of chronic disease and autoimmunity (Box 1).
Early investigations revealed that Il6 −/− mice display various immunological defects, including impaired humoral immunity (for example, mucosal IgA antibody responses), an inability to mount an effective antimicrobial host defence against bacterial, fungal and viral infections, and a reduced capacity for wound healing 30, 124, 125 . In experimental models of autoimmune or inflammatory diseases, including inflammatory arthritis, multiple sclerosis, renal injury and scarring, multicentric Castleman disease and plasmacytoma, Il6 −/− mice display a highly protective phenotype and show limited histological evidence of pathology 5, 126 . The administration of blocking anti-IL-6 or anti-IL-6R antibodies or sgp130 to wild-type mice often recapitulates these findings and has supported the development of biological drugs against IL-6 (refs 5, 15, 37 ).
At sites of disease, members of the IL-6 cytokine family drive inflammation-induced tissue damage. These activities are highly context-dependent but invariably distort the physiological turnover of extracellular matrix and tissue remodelling. This is particularly evident in episodes of fibrosis, where IL-6, IL-11, IL-31 and OSM contribute to fibrotic lesions in the liver, lung, heart, skin, kidney and peritoneal cavity 79, 102, [127] [128] [129] [130] [131] . The development of these fibrotic events typically involves a loss of immune homeostasis and the physiological maintenance of tissue integrity. In particular, fibrosis and scarring often arise from an altered expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases and the regulation of angiogenesis and vasculopathy. Several of these outcomes involve partnerships with other pro-fibrotic cytokines (for example, IL-4, IL-13, TGFβ, CNTF and IFNγ) and the expansion of effector CD4 + T cell populations that shape inflammatory activities within the stromal tissue compartment 79 136, 137 . These observations reflect findings from animal models where IL-6 drives renal inflammation, tissue damage and increased proteinuria 85 . However, the role of IL-6 in kidney disease may also relate to a breakdown in the homeostatic contribution of IL-6 to normal kidney function. For example, in tubular epithelial cells, IL-6 acts to preserve renal function and prevent damage of the epithelial lining 138 . Similar scenarios are also seen in the lung and gut, where IL-6 (via trans-signalling) juggles the balance between homeostatic control of epithelial function and barrier integrity and the onset of pulmonary airway or colitis-like inflammation 49, 139, 140 . In inflammatory or degenerative forms of arthritis, members of the IL-6 cytokine family promote synovial hyperplasia, maintenance of joint inflammation and damage to the underlying cartilage and bone. These hallmarks of disease are primarily regulated by STAT3, whose activity is largely confined to the synovial lining and to clusters of CD3 + T cells within the inflamed synovium 7, [141] [142] [143] [144] . For example, gp130 knock-in mice, which display exaggerated JAK-STAT signalling, show worse joint pathology and heightened synovial inflammation in a model of arthritis 111, 144, 145 . Indeed, a monoallelic deletion of Stat3 in these mice reduces the recruitment and retention of inflammatory leukocytes, improves joint pathology and decreases disease activity [144] [145] [146] [147] . In this regard, IL-6, IL-11, IL-27, OSM and LIF have important effects on both cartilage and bone erosion via their regulatory actions on bone turnover and receptor activator of NF-κB ligand (RANKL; also known as TNFSF11)-mediated osteoclastogenesis [148] [149] [150] [151] [152] [153] . Clinical correlates and experimental studies emphasize that IL-6 transsignalling coordinates many of these outcomes and is an important determinant of leukocyte infiltration and the severity of joint destruction 34, 144, [154] [155] [156] [157] [158] . Consequently, IL-6 trans-signalling is now considered the main protagonist of local IL-6-driven pathology, and therapeutic targeting of this mode of IL-6 signalling in animal models of inflammatory disease frequently leads to improved disease outcomes 5, 37 . While STAT3 activation by IL-6 family cytokines promotes disease processes, the contribution of cytokine signalling through STAT1 often appears to dampen disease activity 3, 37 . This is illustrated by studies in Il27ra −/− mice, which display severe tissue pathology in models of infection and autoimmunity 94, 159 . Although some of these effects relate to the impact of IL-27 on effector T cell populations, IL-27 also directs various tissue-specific responses in antigen-presenting cells, innate immune cells and B cells, as well as other stromal cells 67, 94, 159 . One interesting feature of the tissue pathology seen in Il27ra −/− mice is the development of ectopic lymphoid-like structures (ELSs) at sites of inflammation. These organized lymphoid aggregates are often seen in infection, autoimmunity and cancer, and their presence determines clinical outcome or response to therapy 160 .
In synovial biopsy samples from patients with rheumatoid arthritis and early or established disease, inverse correlations exist between IL-27p28 and the development of highly organized lymphoid-rich aggregates and autoantibody production 161 . Patients with this form of lymphoid-rich synovitis typically display severe or rapidly progressing disease and show poor responses to standard biological drugs 160, 162 . Consistent with IL-27 being a negative regulator of ectopic lymphoneogenesis, this inverse relationship is also evident in Il27ra −/− mice, where the experimental onset of inflammatory arthritis is associated with elevated synovial expression of various mediators implicated in lymphoid neogenesis, including homeostatic chemokines (for example, CXCL13, CC-chemokine ligand 21 (CCL21) and CCL19), proinflammatory cytokines (for example, IL-17 and IL-21), follicular dendritic cell markers (for example, CD21) and transcriptional regulators (for example, B cell lymphoma 6 protein (BCL-6)) 161 . Although the precise mechanism of ELS inhibition by IL-27 requires further investigation, these clinical and experimental studies suggest a role for T follicular helper (T FH ) cells or specialized T H 17 cells, the latter of which can promote ELS formation in inflamed tissues from mice with pulmonary inflammation or experimental autoimmune encephalomyelitis 163, 164 . Indeed, several of the genes associated with ectopic lymphoneogenesis are regulated by STAT3 (for example, IL21, CXCL13 and BCL6), and the action of IL-27 in this setting may influence the transcriptional control of T H 17 cell-like and T FH cell-like cells by inflammatory cytokines such as IL-6 and IL-21 (ref.
165
In summary, IL-6-related cytokines play crucial roles in the orchestration of inflammatory processes relevant to the initiation, progression and diversity of disease activities seen in autoimmune and inflammatory diseases (Box 1). As discussed in the next section, many of these responses are relevant to cancer and influence both the pattern of tumour-associated inflammation and the proliferative expansion or tissue invasion of cancerous cells.
Contrasting roles in cancer
Dysregulated IL-6 family cytokine expression and downstream receptor signalling are frequent events in cancer and are often associated with poor clinical outcomes 4, [166] [167] [168] [169] . In this regard, the pro-tumorigenic actions of IL-6 cytokine family members are elicited by both direct intrinsic effects on cancer cell activities (for example, cell proliferation, survival, migration, invasion and metastasis) and indirect effects on the stromal cell compartment, such as modulation of inflammation, immunosuppression and angiogenesis, which shape the local tumour microenvironment 4,166-170 ( fig. 2) . Furthermore, the link between these cytokines and cancer extends to the recent evidence that some family members (for example, IL-6) are important regulators of energy metabolism (Box 2), which is considered a hallmark feature of the initiation and progression of tumour growth 119, 120, 123 . Paradoxically, accumulating evidence suggests that some IL-6 family cytokines can also mount antitumour responses. The challenge, therefore, is to discern how the dynamic interplay between pro-tumorigenic and antitumorigenic activities arises in different tissue compartments and how this interplay influences responses to biological drugs or immunotherapies that modulate cytokine activity.
Tumour cell-intrinsic effects. IL-6 is the prototypical pro-tumorigenic cytokine within the IL-6 cytokine family and regulates various STAT3-mediated oncogenic processes 6, 52, 68, 168 ( fig. 2 ). For example, IL-6 potentiates the transcriptional induction of numerous molecular targets essential for cell cycle progression and survival (for example, G1/S-specific cyclin D1, the proto-oncogene MYC, BCL-X L , the apoptosis inhibitor survivin (also known as BIRC5) and the microRNA miR-21), angiogenesis, and tumour invasion and metastasis (for example, hypoxia-inducible factor 1α (HIF-1α), matrix metalloproteinase 2 (MMP2), MMP7, MMP9 and vascular endothelial growth factor (VEGF)) 59, 60, 146, 166 . Thus, IL-6 contributes to both the initiation and the rapid progression of tumorigenesis. In late-stage disease, IL-6 also propagates the metastatic spread of invasive cancer cells by inducing transcriptional activators of EMT, such as zinc-finger protein SNAI1 and twist-related protein (TWIST) 171 . Importantly, the growth-potentiating effects of IL-6 on cancer cells also extend to cancer stem cells, whose self-renewal and population expansion requires STAT3 in concert with stem cell transcription factors such as the homeobox protein NANOG 172 . These interactions ultimately contribute to the progression of several multidrug-resistant epithelial and haematologic malignancies 172 . IL-11, LIF and OSM also display cancer cellautonomous pro-tumorigenic activities, many of which overlap with those of IL-6. For example, in cancers of the gastrointestinal tract and breast, IL-11 directly fuels tumour growth by inducing STAT3-regulated gene and miRNA networks that promote cell cycle progression, anti-apoptotic activities and angiogenesis 4, 169, 170, 173 . In gastric cancer, the IL-11-STAT3 axis can promote expression of a TLR2 innate sensing mechanism essential for gastric tumour cell proliferation and survival 169 .
In addition, IL-11, LIF and OSM utilize JAK-STAT3 and PI3K-AKT-mTOR pathways to promote EMTassociated cancer cell invasion and metastasis (including that of bone) and the self-renewal and expansion of cancer stem cell populations [174] [175] [176] [177] . Indeed, the activation of these pathways by OSM and LIF often propagates resistance to targeted therapies and is relevant to both breast and lung cancers 178, 179 . Although the cancer cell-intrinsic actions of CLCF1, CNTF, CT-1, IL-27 and IL-31 family members are less defined, emerging evidence suggests that IL-31 is pro-tumorigenic in some lymphomas 18 . Despite the use of shared receptor signalling pathways, some cytokines within the IL-6 family display opposing antitumour effects on cancer cells. For instance, in a phosphatase and tensin homologue (PTEN)-deficient prostate cancer model, IL-6-STAT3 signalling in tumour cells protects against tumour progression by maintaining an intact senescence-inducing ARF-MDM2-p53 tumour suppressor axis 180 . The antitumour effects of this family are also illustrated by comparing the properties of IL-27 and OSM in various epithelial and haematological malignancies. Here, a regulatory interplay exists between STAT1 and STAT3, whereby IL-27 and OSM (via STAT1) counteract various STAT3-driven processes linked with tumour cell survival, proliferation, metastatic invasion and angiogenesis 181, 182 . This differential switch in shared signalling pathways provides an attractive molecular explanation for the opposing pro-tumorigenic and antitumorigenic activities of the broader IL-6 cytokine family. More investigations are required, however, to establish how the balance of STAT1 and STAT3 signalling shapes the transcriptional landscape in different stages of neoplastic progression and within the tumour microenvironment.
Tumour cell-extrinsic effects. The tumour microenvironment of most cancers is immune cell rich and immunosuppressive and often under the influence of the complex immunomodulatory actions of the IL-6 family cytokines. The nature of this milieu has placed a heavy emphasis on research that aims to understand how these cytokines influence cancer inflammation and tissue remodelling in and around the tumour site, as well as the access and bioactivities of anticancer immunotherapies. Among IL-6 family cytokines, IL-6 elicits the most defined impact on the tumour microenvironment by promoting chronic inflammation that supports tumour angiogenesis and the outgrowth of transformed cells while suppressing T H 1 cell-mediated antitumour immunity 183 ( fig. 2) . These pro-tumorigenic activities impact on the recruitment, retention and activity of tumour-infiltrating leukocytes and are equally as diverse as the pleiotropic innate and adaptive immune responses mediated by IL-6 in autoimmune and chronic inflammatory diseases. Specifically, the pro-tumorigenic effects of IL-6 include the generation of pathogenic T H 17 cells and myeloid-derived suppressor cells (MDSCs), the suppression of antigen-presenting dendritic cells and antitumour cytotoxic CD8 + T cells and T reg cell activity and the phenotypic switching of tumour-associated macrophages from a tumoricidal M1-type phenotype to an immunosuppressive M2-type macrophage phenotype 183 . While further research is required in this area, we expect that other members of the IL-6 cytokine family may elicit similar outcomes. For example, IL-11 promotes inflammation-associated tumorigenesis in the gastrointestinal tract and shares the capacity with IL-6 to polarize T cells and macrophages towards a more immunosuppressive phenotype 4, 170, 173, 184 . In addition to its effects on tumour-associated immune cells, the activities of IL-6 on cancer-associated fibroblasts and adipocytes have attracted considerable interest for their indirect tumour-promoting effects. Because the interplay between IL-6 and fibroblasts in cancer has been covered elsewhere 185 , we summarize here the recent evidence for IL-6 being an adipocytesecreted cytokine ('adipokine') with the potential to modulate interactions between inflammatory and metabolic processes intrinsic to carcinogenesis. This idea is extremely relevant, given the increased risk of cancer in obese individuals with metabolic disorders, which are associated with heightened systemic inflammation. The activities of IL-6 as an adipokine, however, have been largely explored in the context of the paraneoplastic syndrome of cachexia, which is typified by wasting of adipose and muscle tissue 122 . For example, in murine models of lung cancer-associated and pancreatic cancer-associated cachexia, IL-6 promotes an increase in the proportion of brown fat within inflamed adipose tissue. These changes lead to enhanced mitochondrial activity and associated systemic metabolic responses that increase energy expenditure and wasting 122 . Furthermore, the intricate interplay between IL-6-mediated suppression of tumour immunity and dysregulated metabolism is also observed in colorectal and pancreatic cancer cachexia models 123 . Here, tumour-derived IL-6 acts as a pivotal molecular switch between pre-cachectic and active cachectic states by impairing hepatic ketogenesis, which upon restricted caloric intake triggers a metabolically driven cachexia that negates antitumour immunity 123 . Despite the functional redundancy among IL-6 family cytokines, the preponderance of evidence that IL-6 is the primary mediator of hepatic function, metabolism and immunity (Boxes 1,2) suggests that the pathologic actions of this family in cancer-associated cachexia are restricted to IL-6.
In contrast to IL-6, IL-27 displays potent antitumour activities in the tumour microenvironment, which reflect the opposing actions described for these cytokines in autoimmune and inflammatory conditions. Studies in either Il27p28 −/− or Il27ra −/− mice and studies in mice treated with recombinant IL-27 show that this cytokine potentiates antitumour responses through effects on innate and adaptive immune cells 186 . These include IL-27-mediated control of antitumorigenic M1-type macrophages, the suppression of MDSCs, the activation of cytotoxic CD8 + T cells and the production of IFNγ and perforin by cytolytic NK cells and natural killer T cells 186 . Collectively, this powerhouse of antitumour activity has set the stage for IL-27 to be developed further for potential clinical application as an anticancer agent.
Therapeutic strategies
Drug strategies that target IL-6 cytokine family members fall into various categories: blocking monoclonal antibodies that directly act on either the cytokine or the cytokine receptor; recombinant cytokine regimes; and small-molecule therapies that interfere with cytokine receptor signalling through gp130 and the JAK-STAT pathway ( fig. 3 ). While some of these modalities are in routine clinical practice, others remain in various stages of trial development. The challenge facing pharmaceutical companies is to understand the types of clinical indications that may benefit from these therapies and to evaluate the best approach to target these inflammatory cytokines. For example, does inhibition of a cytokine, its corresponding receptor or its mode of cytokine receptor signalling provide optimal therapeutic opportunities or clinical outcomes? These considerations are most pertinent considering that, as discussed previously, certain cytokine receptors (for example, IL-6Rα) bind to more than one cytokine 2, 27, 32, 36 . Thus, therapeutic targeting of these receptor complexes may have wider consequences than inhibiting an individual cytokine. In this regard, Il6 −/− and Il6ra −/− mice display phenotypic differences in wound healing, colitis severity and control of glucose metabolism 5 . The rationale for therapeutic strategies based on blocking monoclonal antibodies is best described for IL-6 (ref.
187 ). These originate from studies of multiple myeloma, where levels of IL-6 and sIL-6R are indicative of tumour severity and treatment with an anti-IL-6 monoclonal antibody halted tumour expansion 188 . Although the pharmacodynamics associated with IL-6 blockade led to a worrying elevation in systemic IL-6 levels 189 , the success of this intervention study nonetheless informed the design of several alternative IL-6-directed therapies. These include the anti-IL-6R blocking monoclonal antibodies tocilizumab and sarilumab, which are recommended for the treatment of inflammatory arthritis, juvenile idiopathic arthritis, adult-onset Still disease, multicentric Castleman disease, cytokine release syndrome (including that associated with chimeric antigen receptor (CAR) T cell therapy) and giant cell arteritis [10] [11] [12] [190] [191] [192] [193] [194] . In rheumatoid arthritis, tocilizumab and sarilumab are also prescribed as monotherapies for patients displaying an inadequate or adverse response to methotrexate 3, 195 . Structure-function studies have identified amino acid motifs essential for IL-6 engagement with IL-6R and their interaction with gp130 (refs 5,196 ). These were instructive for the rationale design of tocilizumab and sarilumab, as well as the IL-6 targeting monoclonal antibodies sirukumab, siltuximab and clazakizumab 5, 178 ( fig. 3 ). Additional biological drugs including olokizumab and EBI-031 prevent the interaction of IL-6 with gp130, while olamkicept (an engineered chimeric sgp130 protein that may target cytokine trans-signalling by IL-6 and IL-11) 46 , NI-1201 (an anti-IL-6R monoclonal antibody) and VHH6 (a junctional epitope nanobody that recognizes the IL-6-IL-6R complex) selectively inhibit IL-6 trans-signalling 5, 27, 46, [197] [198] [199] . These drugs show considerable promise in preclinical studies, early clinical trials and routine clinical practice ( fig. 3 ), although we note that the US Food and Drug Administration (FDA) has recently rejected approval of sirukumab owing to safety concerns.
Another major challenge facing pharmaceutical companies is to differentiate these drugs in terms of their efficacy and safety 3, 8 . For example, clinical experience with tocilizumab therapy shows that patients often develop neutropenia and adverse effects, such as increased infections [200] [201] [202] [203] [204] . Although therapeutic blockade of IL-6 promotes neutropenia, tocilizumab does not promote neutrophil cell death or an increase in nonphlogistic phagocytosis by monocytic cells 205 . Instead, the development of neutropenia may reflect the role of IL-6 in controlling granulopoiesis 206 . In this regard, the incidence and type of infections associated with tocilizumab intervention are similar to those seen with other biological drugs. Here, infections typically occur at epithelial surfaces and mucosal barriers (for example, the upper and lower respiratory tract and the urinary and gastrointestinal tracts), where IL-6 ensures the maintenance of immune homeostasis 3, 8, 207, 208 . This is reflected 
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www.nature.com/nri by the incidence of adverse bacterial infections of the skin that arise in response to tocilizumab treatment of atopic dermatitis 207 . As a consequence, tocilizumab therapy appears less effective in diseases where IL-6 contributes to epithelial homeostasis or barrier integrity 5 . Thus, a prior incidence of gastric perforations or associated diverticulitis is considered a contraindication for the use of tocilizumab 5, 37 . In hindsight, infections on barrier surfaces may have been predicted on the basis of the known biology of IL-6 and its predominant usage of the JAK-STAT3 pathway. For example, patients possessing inhibitory autoantibodies against IL-6 or displaying genetic mutations within the JAK-STAT signalling cassette frequently develop recurrent staphylococcal cellulitis and subcutaneous abs cesses 50, 51, 53, 209 . Indeed, patients with autosomal dominant hyper-immunoglobulin E syndrome (Job syndrome), which is associated with STAT3 deficiency, experience recurrent bacterial infections of the skin and lungs and typically suffer from eczema 53 . These observations highlight the need to predict the involvement of IL-6 in the underlining pathology using stratification criteria that maximize patient response rates. This is epitomized for rheumatoid arthritis, where despite IL-6 or IL-6R inhibition being highly efficacious, some patients still display an inadequate response to therapy 3, 7, 8, 195 . Other effects associated with IL-6 blocking interventions include alterations in serum lipid profiles and liver transaminases 210, 211 . With respect to the former, tocilizumab leads to augmented levels of low-density and high-density lipoprotein C, as well as changes to the composition of cholesterol 211 . Furthermore, tocilizumab suppresses levels of cholesterol-associated clinical biomarkers of cardiovascular risk, namely, high-density lipoprotein-associated serum amyloid A, secretory phospholipase A2 and lipoprotein A 212 . Thus, targeting IL-6 may be of clinical benefit in treating cardiovascular conditions, including pulmonary arterial hypertension 213 . In this regard, the risk of cardiovascular events associated with tocilizumab is comparable to that seen with other agents (for example, tumour necrosis factor (TNF) inhibitors) 214 . However, tempering this notion is the recent observation that tocilizumab treatment of individuals with systemic vasculitis (Kawasaki disease) may cause increased risk of cardiovascular complications, such as coronary artery aneurysms 215 . In addition, serious adverse infections (such as those associated with tocilizumab and other classes of biological drug therapies) can predispose individuals to myocardial infarction or stroke 216 . Notably, systemic inflammation is also commonly associated with an increased risk of cardiovascular disease 211 , suggesting that biological drugs that preferentially control inflammation over lipid profiles afford greater protection against cardiovascular events. For example, therapeutic targeting of the pro-inflammatory cytokine IL-1β with canakinumab significantly lowers the rate of recurrent cardiovascular events (myocardial infarction and stroke) but has a negligible effect on circulating lipids 217 . Therefore, biological drugs that preferentially target systemic inflammation (for example, anti-IL-1 therapy), rather than circulating lipids (for example, anti-IL-6 therapy), may provide a more effective cardio-protective intervention.
As discussed earlier, IL-6 has a major influence on the proliferation, survival and metastatic properties of cancerous cells, and studies using preclinical mouse models indicate that treatments targeting IL-6 or its receptor display therapeutic efficacy as anti cancer agents 6 . As a consequence, several phase I/II clinical trials have evaluated the therapeutic application of tocilizumab, clazakizumab and siltuximab in prostate, lung and breast cancers, multiple myeloma and cancer cachexia [218] [219] [220] . While patients have shown a poor clinical response to these therapies, current trials have been restricted to non-stratified patient cohorts and highlight the need to identify predictive biomarkers for precision medicine approaches incorporating IL-6-directed therapies. Despite these poor clinical outcomes, such therapies can be exploited in cancer to counteract adverse symptoms associated with cancer immunotherapy, such as hypotension, fatigue, nausea, shivering and enhanced acute-phase protein responses. This is particularly evident in CAR T cell therapy, where severe fever responses, hypercytokinaemia and life-threatening forms of 'cytokine storm' can be controlled by treatment with tocilizumab 221, 222 . In addition to IL-6, the association between OSM activity and various disease states has led to the development of a humanized anti-OSM monoclonal antibody (GSK315234). However, a phase II trial designed to examine the safety, tolerability and efficacy of GSK315234 in patients with active rheumatoid arthritis showed no significant improvement in disease activity 223 . Interestingly, this lack of efficacy was attributed to an inferior binding affinity and off-rate kinetics of GSK315234 as compared with the high-affinity interaction of OSM with its receptor. Therefore, future clinical trials with high-affinity anti-OSM antibodies are anticipated in not only patients with rheumatoid arthritis but also patients with inflammatory bowel disease, where high OSM and OSMRβ expression in intestinal tissues correlates with a lack of response to anti-TNF agents 224 . The anti-inflammatory properties of IL-6 family members in numerous in vivo disease models have led to the design of cytokine therapies that promote the action of CNTF, LIF, IL-11 and IL-27. For example, clinical trials have attempted to exploit the neurotrophic properties of CNTF in the treatment of degenerative diseases associated with the brain (for example, Huntington disease) and eye (for example, retinitis pigmentosa and age-related macular degeneration) [225] [226] [227] . However, adverse events including severe weight loss, hyperalgesia, coughing, muscle fatigue and pain have led to the suspension of these studies. Similarly, a trial with recombinant IL-11 in patients with rheumatoid arthritis was also ineffective 228 . Nonetheless, therapeutic strategies based on the neuroprotective properties of LIF and the anti-inflammatory characteristics of IL-27 may offer more promising applications in the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune or inflammatory diseases 152, [229] [230] [231] . Several small-molecule designer drugs have been developed to mimic cytokine-cytokine receptor engagement or to moderate gp130 receptor signalling [232] [233] [234] [235] ( fig. 3 ). For example, regulator of cartilage growth and differentiation-423 (RCGD-423) promotes a transient activation of gp130 dimerization and signalling 232 . With applications in the treatment of osteoarthritis, RCGD-423 prevents chondrocyte hypertrophy and cartilage destruction in rat models of disease and promotes chondrocyte proliferation and survival 232 . Other modalities that interfere with gp130 signalling include madindoline-A, the small-molecule inhibitor SC144 and the synthetic oxazolidinone derivative LMT-28 (refs 233-235 ). While the clinical utility of these drugs requires further investigation, SC144 has been touted as a small-molecule gp130 inhibitor for the treatment of ovarian cancer 233 . Another class of drug intervention, which is not selective for gp130 cytokine receptor signalling but has generated substantial attention over recent years, is based on blockade of the JAK-STAT3 axis 6, 9 . The most advanced drugs of this type include tofacitinib, ruxolitinib, oclacitinib and baricitinib, which target JAK1, JAK2 or JAK3 (ref. 236 ). These JAK inhibitors are potent diseasemodifying agents and are approved or in clinical trials for the treatment of rheumatoid arthritis, psoriasis, myelofibrosis and other forms of autoimmune disease and cancer 236 . Similarly, various anti-sense oligonucleo tide inhibitors (for example, AZD9150, which targets STAT3), www.nature.com/nri modulators of inhibitory SOCS3 activity, natural chemical blockers of STAT3 activity (for example, curcumin and capsaicin) and inhibitors of STAT3 binding to DNA (for example, CPA-1 and CPA-7) are also considered promising therapies for these diseases [237] [238] [239] [240] [241] (fig. 3 ).
Concluding remarks
The IL-6 cytokine family is arguably the most complex group of related cytokines and affects all major biological systems within the body. In this respect, IL-6 family members are essential for development, reproduction, tissue regeneration, immune homeostasis and defence and repair from infection, trauma or injury. However, their involvement in chronic disease and cancer identify them as diagnostic indicators, markers of disease activity and targets of therapeutic intervention. With such widespread and often overlapping properties, the challenge remains to establish how the individual characteristics of these cytokines contribute to disease progression and the comorbidities presented by patients with complex chronic and malignant illnesses. This is especially pertinent to drug discovery, the development of combinationtype interventions and investigations that differentiate drug action. Despite much preclinical promise, very few efficacious therapies against members of this cytokine family have reached the clinic since the approval of tocilizumab in 2009. Although small-molecule interventions (for example, JAK inhibitors) offer opportunities to target intracellular components of the gp130 cytokine receptor cassette, they also act on other cytokines that use common or alternative JAK-STAT signalling mechanisms. However, an improved understanding of the molecular interactions that underpin ligand-receptor assembly and cytokine receptor signalling has seen a rapidly expanding number of next-generation agonists and antagonists for gp130 or specific family members, including IL-6, IL-11, IL-27, LIF and OSM. As we acquire new insights into the mechanisms driving local pathology, and the contribution of the immune system to mental health and physical and psychological well-being, the challenge is to establish whether these agents not only decrease disease activity but also improve the overall quality of life of patients with chronic or debilitating disease. The coming decade therefore holds considerable promise and offers exciting opportunities to explore the therapeutic application of cytokine-directed drugs in the clinical management of autoimmune, infectious and inflammatory diseases, as well as cancers.
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